Treatment of physician's choice
Sponsors
Hoffmann-La Roche, Chinese Academy of Medical Sciences, Sun Yat-sen University, Peking Union Medical College Hospital, BriaCell Therapeutics Corporation
Conditions
Breast CancerBreast Cancer MetastaticBreast NeoplasmEarly-stage Breast CancerEnd Stage CancerHER2-positive Breast CancerMetastatic Breast Cancer
Phase 2
Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients
NCT02829008
Start: 2016-04-30End: 2020-04-30Target: 120Updated: 2016-07-12
A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
NCT03997539
Start: 2019-08-15End: 2021-12-30Target: 256Updated: 2019-06-25
Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.
RecruitingNCT07227233
Start: 2026-04-01End: 2028-12-01Target: 105Updated: 2026-02-18
Phase 3
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy
CompletedNCT01419197
Start: 2011-09-30End: 2015-08-31Updated: 2016-10-12
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
RecruitingNCT06072612
Start: 2023-12-05End: 2028-06-01Target: 404Updated: 2026-04-02
Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib
RecruitingNCT06341621
Start: 2024-04-02End: 2029-01-01Target: 1900Updated: 2024-04-10